Lexicon Pharmaceuticals (LXRX) has disclosed a new risk, in the Capital Markets category.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lexicon Pharmaceuticals faces significant business risks due to potential disruptions in its supply chain caused by changes in government trade policies. The company’s reliance on third-party manufacturers in Canada and China for the production and packaging of INPEFA and other drug candidates makes it vulnerable to proposed tariffs and import/export restrictions. Such policy changes could hinder the availability of commercial products and clinical developments, while also increasing costs for raw materials sourced internationally, thereby affecting the company’s competitive pricing and financial performance. The unpredictability of future trade policy adjustments further exacerbates these risks, posing a threat to Lexicon Pharmaceuticals’ operational stability.
The average LXRX stock price target is $3.67, implying 836.70% upside potential.
To learn more about Lexicon Pharmaceuticals’ risk factors, click here.